Regeneron (REGN) Says EYLEA Clinically Equivalent to Lucentis Following VIEW 1, 2 Phase 3s
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
Go back to Regeneron (REGN) Says EYLEA Clinically Equivalent to Lucentis Following VIEW 1, 2 Phase 3s
October 22, 2012 2:26 PM EDT
Leerink Swann reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $182.00 (from $150.00).
MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that... More